# US 2019/0375833 A1 · Use of tgf-alpha polypeptide or anti-tgf-alpha antibodies for the treatment of diseases and disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375833 A1
- Document ID: US20190375833A1
- Status: Published application
- Kind: A1
- Application number: 16/534,691
- Filed: 2019-08-07
- Published: 2019-12-12
- Earliest claimed: 2017-02-17
- Inventors: George J. Todaro
- Web page: https://patentgrep.com/patent/US20190375833A1

## CPC

- A61K 38/1841: {Transforming growth factor [TGF]}
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/18: Growth factors; Growth regulators
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2039/505: {comprising antibodies}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides a method of treating a disease or disorder in a subject by inducing a TGF alpha immune response or by administering an anti-TGF-alpha antibody or a biologically active fragment thereof. The TGF-alpha immune response is induced using a TGF-alpha polypeptide or biologically active fragment, a vaccine, a genetic construct or a transformed cell, for example.

## Claims

### Claim 1

A composition for administration to a subject to produce an immune response against TGF-alpha comprising a TGF-alpha polypeptide or a biologically active fragment thereof.

### Claim 2 (depends on 1)

The composition of claim 1, further comprising a checkpoint inhibitor.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the checkpoint inhibitor inhibits PD-1, PD-L1, PD-L2 or CTLA-4.

### Claim 4

A composition for administration to a subject to produce an immune response against TGF-alpha comprising a nucleic acid molecule encoding a TGF-alpha polypeptide or a biologically active fragment thereof.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the nucleic acid is DNA or RNA.

### Claim 6 (depends on 1, 4)

The composition of claim 1 or 4, further comprising an adjuvant.

### Claim 7

An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a nucleic acid sequence encoding a TGF-alpha protein or biologically active fragment thereof, a transmembrane domain and an intracellular signaling domain.

### Claim 8 (depends on 7)

The nucleic acid molecule of claim 7, wherein the transmembrane domain comprises a transmembrane domain of a protein selected from the group consisting of the TGF-alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154.

### Claim 9 (depends on 7)

The nucleic acid molecule of claim 7, wherein the nucleic acid sequence encoding the TGF-alpha polypeptide or biologically active fragment is connected to the transmembrane domain by a linker or hinge region.

### Claim 10

A chimeric antigen receptor (CAR) polypeptide, wherein the CAR comprises a TGF-alpha protein or biologically active fragment thereof, a transmembrane domain and an intracellular signaling domain.

### Claim 11 (depends on 10)

The polypeptide of claim 10, wherein the transmembrane domain comprises a transmembrane domain of a protein selected from the group consisting of the TGF-alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154.

### Claim 12 (depends on 10)

The polypeptide of claim 10, wherein a nucleic acid encoding the TGF-alpha polypeptide or biologically active fragment is connected to the transmembrane domain by a linker or hinge region.

### Claim 13 (depends on 7, 8, 9, 10, 11, 12)

A method of providing anti-tumor immunity in a subject, comprising administering to the subject an immune cell comprising the nucleic acid molecule of any of claims 7-9 or the polypeptide of any of claims 10-12.

### Claim 14

A pharmaceutical composition comprising a TGF-alpha polypeptide or biologically active fragment thereof and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 14)

The composition of claim 14, further comprising a checkpoint inhibitor.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the checkpoint inhibitor inhibits PD-1, PD-L1, PD-L2 or CTLA-4.

### Claim 17

A method of treating a TGF-alpha related disease or disorder in a subject comprising administering to the subject a therapeutically effective amount of a TGF alpha polypeptide or a biologically active fragment thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the TGF-alpha related disease or disorder is cancer or an immune disorder.

### Claim 19 (depends on 18)

The method of claim 18, wherein the cancer is selected from the group consisting of lung, stomach, prostate, colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, melanoma and urogenital tract.

### Claim 20 (depends on 19)

The method of claim 19, wherein the cancer is colon, stomach, lung or head and neck cancer.

### Claim 21 (depends on 18)

The method of claim 18, wherein the immune disorder is selected from the group consisting of Rheumatoid arthritis, Systemic lupus erythematosus, Celiac disease, Crohn's disease, Inflammatory bowel disease, Sjogren's syndrome, Polymyalgia rheumatic, Psoriasis, Multiple sclerosis, Ankylosing spondylitis, Type 1 diabetes, Alopecia areata, Vasculitis, Temporal arteritis, Graves' disease and Hashimoto's thyroiditis.

### Claim 22 (depends on 17)

The method of claim 17, wherein the TGF-alpha polypeptide or biologically active fragment thereof has at least 75% identity to the amino acid sequence of any of SEQ ID NOs: 5-8 or 10.

### Claim 23 (depends on 17)

The method of claim 17, wherein the TGF-alpha polypeptide or biologically active fragment thereof is a fusion protein.

### Claim 24 (depends on 17)

The method of claim 17, wherein the TGF-alpha polypeptide or biologically active fragment thereof is genetically modified.

### Claim 25 (depends on 17)

The method of claim 17, wherein the TGF-alpha polypeptide or biologically active fragment thereof comprises a heterologous sequence.

### Claim 26 (depends on 17)

The method of claim 17, further comprising administering to the subject a chemotherapeutic agent, radiation and/or an immune modulator either prior to, simultaneously with or following treatment with the TGF-alpha polypeptide or biologically active fragment thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the chemotherapeutic agent is selected from the group consisting of Actinomycin, Azacitidine, Azathioprine, Bleomycin, Bortezomib, Carboplatin, Capecitabine, Cisplatin, Chlorambucil, Cyclophosphamide, Cytarabine, Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Epothilone, Etoposide, Fluorouracil, Gemcitabine, Hydroxyurea, Idarubicin, Imatinib, Irinotecan, Mechlorethamine, Mercaptopurine, Methotrexate, Mitoxantrone, Oxaliplatin, Paclitaxel, Pemetrexed, Teniposide, Tioguanine, Topotecan, Valrubicin, Vinblastine, Vincristine, Vindesine, Vinorelbine, panitumamab, Erbitux, matuzumab, IMC-IIF 8, TheraCIM hR3, denosumab, Avastin, Humira, Herceptin, Remicade, rituximab, Synagis, Mylotarg, Raptiva, Tysabri, Zenapax, NeutroSpec, tocilizumab, ProstaScint, Bexxar, Zevalin, Xolair, MabThera, ReoPro, MabCampath, Simulect, LeukoScan, CEA-Scan (Verluma, Panorex, alemtuzumab, CDP 870, natalizumab, MGA271, lirilumab, BMS-986016, pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, and iplimumab.

### Claim 28 (depends on 27)

The method of claim 27, wherein the chemotherapeutic agent is pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, and/or iplimumab.

### Claim 29 (depends on 26)

The method of claim 26, wherein the immune modulator is selected from the group consisting of tocilizumab, CDP870, enteracept, adalimumab, Kineret, abatacept, infliximab, rituzimab, golimumab, Avonex, Rebif, ReciGen, Plegridy, Betaseron, Copaxone, Novatrone, natalizumab, fingolimod, teriflunomide, BG12, Tecfidera, and alemtuzumab.

### Claim 30 (depends on 17)

The method of claim 17, further comprising the administration of a checkpoint inhibitor.

### Claim 31 (depends on 30)

The method of claim 30, wherein the checkpoint inhibitor inhibits PD-1, PD-L1, PD-L2 or CTLA-4.

### Claim 32 (depends on 18)

The method of claim 18, wherein the cancer is a tumor.

### Claim 33 (depends on 32)

The method of claim 32, wherein the tumor is resected prior to treatment.

### Claim 34 (depends on 17)

The method of claim 17, wherein the subject is a human.

### Claim 35 (depends on 17)

The method of claim 17, wherein the administration of the TGF-alpha polypeptide or biologically active fragment thereof induces the in vivo production of anti-TGF-alpha antibodies.

### Claim 36 (depends on 17)

The method of claim 17, wherein the TGF-alpha polypeptide or biologically active fragment thereof is administered by intravenous, oral, intramuscular, subcutaneous, intrathecal, infusion, transdermal, sublingual, buccal, rectal, vagina, ocular, optic, nasal, inhalation, nebulization, cutaneous, intraperitoneal or intratumoral administration.

### Claim 37

A method of treating a TGF-alpha related disease or disorder in a subject comprising inducing the in vivo production of anti-TGF-alpha antibodies in the subject.

### Claim 38 (depends on 37)

The method of claim 37, comprising the administration of a TGF-alpha polypeptide or a biologically active fragment thereof.

### Claim 39 (depends on 38)

The method of claim 38, wherein the TGF-alpha polypeptide has at least 75% sequence identity to the amino acid sequence of any of SEQ ID NOs: 5-8 or 10.

### Claim 40 (depends on 38)

The method of claim 38, wherein the TGF-alpha polypeptide or a biologically active fragment thereof is a fusion protein.

### Claim 41 (depends on 38)

The method of claim 38, wherein the TGF-alpha polypeptide or a biologically active fragment thereof is genetically modified or comprises a heterologous sequence.

### Claim 42 (depends on 37)

The method of claim 37, comprising the administration of a TGF-alpha vaccine.

### Claim 43 (depends on 42)

The method of claim 42, wherein the vaccine is a DNA, RNA or peptide vaccine.

### Claim 44 (depends on 37)

The method of claim 37, comprising administering a cell transformed with a nucleic acid molecule encoding a TGF-alpha polypeptide or a biologically active fragment thereof.

### Claim 45 (depends on 44)

The method of claim 44, wherein the cell is transformed with a nucleic acid sequence having at least 75% sequence identity to of any of SEQ ID NOs: 1-4 or 9.

### Claim 46 (depends on 37)

The method of claim 37, wherein the TGF-alpha related disease or disorder is cancer or an immune disorder.

### Claim 47 (depends on 37)

The method claim 37 further comprising administering to the subject a chemotherapeutic agent, radiation or an immune modulator either prior to, simultaneously with or following treatment with the TGF-alpha polypeptide or biologically active fragment thereof, TGF-alpha vaccine or transformed cell.

### Claim 48 (depends on 47)

The method of claim 47, wherein the chemotherapeutic agent is pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, and/or iplimumab.

### Claim 49 (depends on 47)

The method of claim 47, wherein the immune modulator is selected from the group consisting of tocilizumab, CDP870, enteracept, adalimumab, Kineret, abatacept, infliximab, rituzimab, golimumab, Avonex, Rebif, ReciGen, Plegridy, Betaseron, Copaxone, Novatrone, natalizumab, fingolimod, teriflunomide, BG12, Tecfidera, and alemtuzumab.

### Claim 50 (depends on 37)

The method of claim 37, further comprising the administration of a checkpoint inhibitor.

### Claim 51 (depends on 50)

The method of claim 50, wherein the checkpoint inhibitor inhibits PD-1, PD-L1, PD-L2 or CTLA-4.

### Claim 52

A method of treating a TGF-alpha related disease or disorder in a subject comprising administering to the subject a therapeutically effective amount of an anti-TGF-alpha antibody or a biologically active fragment thereof.

### Claim 53 (depends on 52)

The method of claim 52, wherein the TGF-alpha related disease or disorder is a TGF-alpha-producing tumor.

### Claim 54 (depends on 52)

The method of claim 52, further comprising administering to the subject a chemotherapeutic agent, radiation and/or an immune modulator either prior to, simultaneously with or following treatment with the anti-TGF-alpha antibody or biologically active fragment thereof.

### Claim 55 (depends on 52)

The method of claim 52, further comprising the administration of a checkpoint inhibitor.

### Claim 56 (depends on 55)

The method of claim 55, wherein the checkpoint inhibitor inhibits PD-1, PD-L1, PD-L2, CTLA-4 or CD137.

### Claim 57 (depends on 52)

The method of claim 52, wherein the therapeutically effective amount of an anti-TGF-alpha antibody or a biologically active fragment thereof is sufficient to induce a T cell activation.

### Claim 58 (depends on 56)

The method of claim 56, comprising administering a TGF-alpha antibody in combination with an anti-PD1 antibody.

### Claim 59 (depends on 58)

The method of claim 58, further comprising administering an anti-CTLA4 antibody.

### Claim 60 (depends on 52)

The method of claim 52, wherein the therapeutically effective amount of anti-TGF-alpha antibody is from about 50-1000 μg/injection.

### Claim 61 (depends on 52)

The method of claim 52, wherein the therapeutically effective amount of antibody is from about 250-500 μg/injection.

### Claim 62 (depends on 61)

The method of claim 61, wherein the injection is from 1-3 times per week.

### Claim 63

A method of inducing T cell activation in a subject comprising administering to said subject a therapeutically effective amount of an anti-TGF-alpha antibody or a biologically active fragment thereof.

### Claim 64 (depends on 58)

The method of claim 58, wherein the subject has a TGF-alpha producing tumor.

### Claim 65

A method of treating cancer in a subject comprising:
identifying a TGF-alpha-producing tumor from a biological sample from the subject, and
administering to the subject a therapeutically effective amount of an anti-TGF-alpha antibody or a biologically active fragment thereof.

### Claim 66 (depends on 60)

The method of claim 60, further comprising the administration of a checkpoint inhibitor.

### Claim 67 (depends on 55)

The method of claim 55, wherein the checkpoint inhibitor inhibits PD-1, PD-L1, PD-L2, CTLA-4 or CD137.

### Claim 68 (depends on 67)

The method of claim 67, comprising administering a TGF-alpha antibody in combination with an anti-PD1 antibody.

### Claim 69 (depends on 68)

The method of claim 68, further comprising administering an anti-CTLA4 antibody.

### Claim 70 (depends on 65)

The method of claim 65, wherein the therapeutically effective amount of anti-TGF-alpha antibody is from about 50-1000 μg/injection.

### Claim 71 (depends on 65)

The method of claim 65, wherein the therapeutically effective amount of antibody is from about 250-500 μg/injection.

### Claim 72 (depends on 71)

The method of claim 71, wherein the injection is from 1-3 times per week.

### Claim 73 (depends on 53, 64)

The method of any of claim 53, 64, or 65, wherein the cancer or the tumor is selected from the group consisting of a cancer or tumor of the lung, stomach, prostate, colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, melanoma and urogenital tract.

### Claim 74 (depends on 73)

The method of claim 73, wherein the cancer is colon, stomach, lung breast, melanoma or head and neck cancer.
